Intracellular inclusions composed of abnormal protein aggregates are one of the neuropathological features of neurodegenerative diseases, and the formation of intracellular aggregates is believed to be associated with neurodegeneration leading to the onset of these diseases. In typical or pure cases, characteristic pathologies with one particular protein, such as tau, alpha-synuclein or transactivation response DNA protein 43 (TDP-43), can be observed in brains of patients. On the other hand, multiple protein pathologies co-exist in many cases, raising the possibility that they may influence each other reciprocally in the pathogenesis and progression of the diseases. However, the molecular mechanisms through which these proteins interact with each other and through which they are co-deposited in brains of patients remain poorly understood. In this review, we focus on the mechanisms of deposition of multiple pathological proteins, such as tau, alphasynuclein and/or TDP-43, and on co-deposition models of these proteins in vitro and in vivo intended to recapitulate the multiple pathologies found in diseased brains.
INTRODUCTION
The accumulation of abnormal protein aggregates in affected neurons and glial cells is a pathological hallmark of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Neurofibrillary tangles and threads composed of microtubule-associated protein tau are hallmarks of AD, while Lewy bodies and Lewy neurites, the signature pathological inclusions of PD and dementia with Lewy bodies (DLB), are composed of alpha-synuclein. In addition, trans-activation response DNA protein 43 (TDP-43) is the major protein component of ubiquitin-positive inclusions found in FTLD and ALS. Previous studies support the view that the formation of intracellular aggregates is related to neuronal cell loss, and these aggregates exhibit characteristic patterns of temporal spreading and topological distribution that correlate with clinical phenotype. [1] [2] [3] Prion-like propagation of intracellular protein aggregates has been suggested to account for the spreading of these pathologies and progression of the diseases. [4] [5] [6] [7] In pure cases, a single typical pathology can be seen in the diseased brain, in which aggregates composed of one abnormal protein characteristic of the disease are accumulated. However, in many cases, patients exhibit aggregation of multiple pathological proteins. It is known that tau is often accumulated in DLB brains, and aggregation of alpha-synuclein is also detected in AD brains. Furthermore, phosphorylated TDP-43 is also often deposited in AD and DLB brains. 8, 9 Similarly, studies using cultured cells and transgenic animals have shown the co-occurrence of abnormal deposition of multiple pathological proteins in in vitro and in vivo models. [10] [11] [12] [13] Here, we present our recent data on the co-deposition of tau and alphasynuclein or TDP-43 and alpha-synuclein in cell culture and mouse models, and we discuss potential mechanisms underlying the co-occurrence of multiple abnormal proteins in vitro and in vivo. reported that alpha-synuclein induces fibrillization of tau, and that co-incubation of recombinant tau and alphasynuclein synergistically promotes fibrillization of both proteins. 10 They revealed that tau aggregation was promoted in the presence of full-length alpha-synuclein, but not beta-synuclein, a homolog of alpha-synuclein that does not fibrillize, or the delta 71-82 truncated form of alpha-synuclein, an artificial mutant of alpha-synuclein that cannot self-fibrillize, suggesting that alpha-synuclein can function as a tau aggregation inducer through its hydrophobic non-amyloid component (NAC) domain. We also showed that alpha-synuclein fibrils, but not monomer, bind to tau and inhibit microtubule assembly in vitro. 13 Using various deletion mutants of alphasynuclein and tau, the acidic C-terminal region of alphasynuclein and the basic central region of tau were identified as regions involved in their binding, in agreement with a previous report. 17 Furthermore, we successfully generated a cultured cell model recapitulating the deposition of both tau and alphasynuclein found in human diseased brains. 13 When recombinant alpha-synuclein fibrils were introduced into cultured SH-SY5Y cells expressing only tau, immunocytochemical analyses of these cells using anti-AT8 confirmed that few inclusions were positive for AT8 (Fig. 1A) . In contrast, not only phosphorylated alpha-synuclein inclusions, but also many phosphorylated tau aggregates positive for AT8 were found in cells expressing both tau and alphasynuclein following treatment with alpha-synuclein fibrils. Some inclusions were positive for both AT8 and pS129, but these proteins were not co-localized in some cells, suggesting that alpha-synuclein fibrils do not necessarily function as cross-seeds for tau aggregation. Immunoblot analyses showed that bands of phosphorylated tau were more abundant in Sarkosyl-insoluble fraction (Sar-ppt) of cells expressing tau and alpha-synuclein after treatment with alpha-synuclein fibrils, compared with the corresponding fraction from cells expressing tau and alpha-synuclein without any treatment (Fig. 1B) . On the other hand, under our conditions, tau 4R1N fibrils did not induce phosphorylated alpha-synuclein aggregation in cells expressing both proteins (data not shown). The reason why tau fibrils could not elicit intracellular alpha-synuclein aggregation is unknown, but the difference of the seeding activity between alpha-synuclein and tau fibrils might be important. These results clearly indicated that alpha-synuclein fibrils induce aggregation of tau in cells expressing both tau and alpha-synuclein.
DEPOSITION OF BOTH ALPHA-SYNUCLEIN AND TAU
Many strains of genetically engineered mice expressing human tau and/or alpha-synuclein have been generated. It is interesting that no phosphorylated tau aggregates were detected in a transgenic line expressing wild-type alphasynuclein, but abundant tau inclusions were observed in mice expressing A53T and E46K mutant forms of alphasynuclein. 10, 19, 20 The alpha-synuclein inclusions were partially co-localized with intracellular tau aggregates in brain stems of A53T mice. Recently, we created a new mouse model with intracellular alpha-synuclein inclusions by stereotaxically injecting recombinant human alphasynuclein fibrils into wild-type mouse brain. 12, 18 We observed that endogenous mouse alpha-synuclein is accumulated after the injection of recombinant human alpha-synuclein fibrils in a seed-dependent manner, and the pathology spreads to neurons in areas far from the injection sites, especially areas with direct neural connections to the injection sites. These results clearly support the possibility that alpha-synuclein aggregates spread by prion-like mechanisms through neural networks in mouse brains. Other researchers have also reported similar results, 21 suggesting a possible role of prion-like spreading of pathology in the brain in various neurodegenerative diseases. 4 Furthermore, we also showed that not only alphasynuclein, but also tau is deposited in mice injected with synthetic alpha-synuclein fibrils into striatum. 12 In these mouse brains, phosphorylated tau aggregates were rarely co-localized with alpha-synuclein pathology, which is very similar to the above results obtained using cultured cells expressing tau and treated with alpha-synuclein fibrils.
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Although the molecular mechanisms through which recombinant alpha-synuclein fibrils induce deposition of endogenous tau in our in vitro and in vivo models are not clear, there seem to be at least two possibilities: (i) alphasynuclein fibrils directly interact with endogenous tau monomer and function as cross-seeds for intracellular tau aggregation; (ii) alpha-synuclein fibrils facilitate aggregation of endogenous tau without direct interaction or crossseeding. In our models, the latter would likely be the case, because tau aggregates did not necessarily overlap with alpha-synuclein inclusions in cultured cells and mouse brains. On the other hand, Guo et al. showed that distinct alpha-synuclein strains promote tau aggregation in vitro and in vivo. 11 They also found that synthetic alphasynuclein fibrils cross-seed tau aggregation.
CO-EXISTENCE OF ALPHA-SYNUCLEIN AND TDP-43 PATHOLOGY IN HUMAN DISEASED BRAINS
There are some reports that phosphorylated TDP-43 pathology exists in AD and DLB, 8, 9 suggesting that alpha- 
SYNTHETIC ALPHA-SYNUCLEIN FIBRILS ALSO INDUCE TDP-43 AGGREGATION IN VITRO AND IN VIVO
In agreement with the immunohistochemical analyses of human diseased brains, co-existence of alpha-synuclein and TDP-43 pathology was also found in mouse brains. We observed phosphorylated TDP-43 pathology in mouse brains injected with recombinant alpha-synuclein fibrils.
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When synthetic alpha-synuclein fibrils were injected into striatum or entorhinal cortex of wild-type mouse brains, phosphorylated TDP-43 pathologies were observed within just 1 month after injection. Phosphorylated TDP-43 was accumulated in dot-like inclusions, but these were rarely co-localized with alpha-synuclein pathology. Additionally, we established a model recapitulating the co-occurrence of alpha-synuclein and TDP-43 inclusions using cultured cells. SH-SY5Y cells were transiently transfected with TDP-43 wild-type (TDP WT) or mutant TDP-43 lacking the nuclear localization signal (TDP dNLS) in the presence or absence of alpha-synuclein, followed by the introduction of synthetic alpha-synuclein fibrils. At 2 days after introduction, cells were harvested and subjected to immunocytochemical and immunoblot analyses. As shown in Figure 2A , no inclusions positive for anti-phosphorylated TDP-43 antibody (anti-pS409/410) were found in cells expressing only TDP dNLS and treated with alpha-synuclein fibrils. On the other hand, abundant aggregates of phosphorylated TDP-43 were observed in cells expressing TDP-43 dNLS and alpha-synuclein after the addition of alpha-synuclein fibrils. In these cells, phosphorylated TDP-43 was partially co-localized with phosphorylated alpha-synuclein, which is similar to the partial co-localization of tau and alpha-synuclein aggregates in cells expressing tau and alpha-synuclein after treatment with alpha-synuclein fibrils, as described above. On the other hand, we observed very few inclusions positive for pS409/410 in cells expressing wild-type TDP-43 and alphasynuclein and treated with alpha-synuclein fibrils (data not shown), suggesting that mislocalized and cytosolic TDP-43 is likely to be more prone to aggregate in cells after the injection of alpha-synuclein fibrils, as compared with wildtype nuclear TDP-43. Immunoblot analyses of these cells showed that the band intensities of phosphorylated and deposited TDP-43 in cells expressing TDP dNLS and alpha-synuclein and treated with alpha-synuclein fibrils are greater than those in cells expressing only TDP dNLS and treated with alpha-synuclein fibrils (Fig. 2B) .
GAIN-OR LOSS-OF-FUNCTIONAL GENE MUTATION INDUCES AGGREGATION OF PATHOGENIC PROTEINS IN VITRO AND IN VIVO
Genetic studies have identified many causative or risk genes for familial forms of neurodegenerative diseases. Some of the gene products (tau, alpha-synuclein, TDP-43, polyQ and fused-in sarcoma) have been found to selfaggregate and affect the survival of cells, but in most cases, it remains unknown how the mutations induce neurodegeneration. Profilin 1 (PFN1) is a causative gene in which missense mutations have been identified in familial ALS. 24 Patients with PFN1 mutation have TDP-43 pathologies, 25 suggesting that PFN1 mutation may induce TDP-43 pathologies. To test whether or not mutant PFN1 may lead to TDP-43 accumulation, we investigated the effect of the mutations on TDP-43 aggregation using 
CONCLUSIONS
How do synthetic alpha-synuclein fibrils induce intracellular tau and TDP-43 aggregation in vitro and in vivo? Given the findings that most alpha-synuclein aggregates are not co-localized with tau or TDP-43 inclusions, either in cultured cells and mouse models treated with synthetic alpha-synuclein fibrils or in human diseased brains, it seems likely that alpha-synuclein fibrils do not necessarily work as direct cross-seeds for aggregation of other intracellular proteins. It remains unclear how alpha-synuclein fibrils could induce aggregation of other proteins in these models, but one possibility is that introduction of the fibrils into cells results in cellular dysfunctions that in turn trigger aggregation of other proteins. For example, it is reported that proteasome activity is inhibited in cells treated with synthetic alpha-synuclein fibrils or insoluble TDP-43 prepared from diseased brains. 22, 32 Impairment of protein degradation systems such as the ubiquitinproteasome system and autophagy has been reported to induce formation of protein aggregates. 33, 34 Thus, the inhibition of protein degradation systems in cells may be necessary for induction of intracellular protein aggregation. Actually, it has been reported that lysosomal function is inhibited in cells expressing mutant PGRN, 35 suggesting that lysosomal dysfunction may lead to aggregation of multiple pathogenic proteins in brains of patients with PGRN mutations. On the other hand, increased aggregation of alphasynuclein in cells expressing alpha-synuclein and tau or TDP-43, followed by addition of alpha-synuclein fibrils, may cause cellular stresses including unfolded protein response (UPR) or endoplasmic reticulum (ER) stress, which may lead to formation of intracellular tau or TDP-43 aggregates. UPR activation is reported to be closely associated with the first stages of accumulation and aggregation of toxic proteins involved in AD and PD. 36 Recent research has also identified ER stress as a major mechanism implicated in cytotoxicity in neurodegenerative diseases. 37 In any case, further studies will be required to uncover the precise molecular mechanisms involved in the co-deposition of multiple pathogenic proteins in cultured cells, mouse models and human brains.
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